Global Human Immunodeficiency Virus (HIV) Market – Industry Trends and Forecast to 2030

Global Human Immunodeficiency Virus (HIV) Market, By Diagnostics (Antigen/Antibody Test, Antibody Test, Nucleic Acid Tests (NATs), CD4T Cell Count, Viral Load, Drug Resistance, Others), Drugs (protease inhibitors (PIs), multi-class combination drugs, fusion inhibitors (FI), Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.

Human Immunodeficiency Virus (HIV) Market Analysis and Size

Increasing cases of human immunodeficiency virus (HIV)-AIDS pushes the human immunodeficiency virus (HIV) market because of the increased sexually transmitted diseases and genetic disruption of CDT4 cells. There were about 5.8 million human immunodeficiency virus (HIV)-infected individuals in Asia Pacific, 20.7 million people in Eastern and Southern Africa, and 2.2 million people in Western & Central Europe and North America. Furthermore, the market is also influenced by the increase in the number of government initiatives for creating the awareness amongst people associated with causes, symptoms and treatments.

 Data Bridge Market Research analyses a growth rate in the human immunodeficiency virus (HIV) market in the forecast period 2023-2030. The expected CAGR of human immunodeficiency virus (HIV) market is tend to be around 6.20% in the mentioned forecast period. The market is valued at USD 32.7 billion in 2022, and it would grow upto USD 52.91 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Human Immunodeficiency Virus (HIV) Market Scope and Segmentation

Market Definition

 Human immunodeficiency virus (HIV)-AIDS is a potentially, chronic life threatening disease which is caused by the human immunodeficiency virus (HIV) (human immunodeficiency virus). It spreads through virus that significantly attack the body immune system. After sometime, the virus can destroy so many immune cells that the body cannot fight back towards infection and disease. human immunodeficiency virus (HIV) drugs assist in preventing the multiplication of human immunodeficiency virus (HIV), thus decreasing the risk of its transmission. 

Human Immunodeficiency Virus (HIV) Market Dynamics

Drivers

• Increasing Cases of Human Immunodeficiency Virus (HIV)

In several developing regions, such as Africa, the cases of human immunodeficiency virus (HIV) infections are increasing rapidly. It is set to boost the human immunodeficiency virus (HIV) drugs market growth. The World Health Organization (WHO) stated that in 2019, around 1.7 million new human immunodeficiency virus (HIV)-infected patients were recorded, while 33.0 million people were living with the infection worldwide. Besides, the Joint United Nations Programme on human immunodeficiency virus (HIV)/AIDS (UNAIDS) stated that there were around 5.8 million human immunodeficiency virus (HIV)-infected individuals in Asia Pacific, 20.7 million people in Eastern and Southern Africa, and 2.2 million people in Western & Central Europe and North America in 2019. The huge patient population across several regions in creating huge demand for antiretroviral drugs or other human immunodeficiency virus (HIV) treatment. Also, the government is taking huge steps to diagnose and treat the patients. Thus, the increasing incidence of human immunodeficiency virus (HIV) is leading the growth of the market.

Opportunities

• Increasing Product Launches by Several Market Players

The increasing importance on R&D activities in the field of human immunodeficiency virus (HIV) drugs is anticipated to result in the growing drug innovations globally. Numerous reputed companies, such as ViiV Healthcare, Boehringer Ingelheim International GmbH, and Gilead Sciences are engaging in different investment initiatives to compete in the market. Some of the other market players are participating in new product launches and collaborations. For instance, in September 2019, Merck Sharp & Dohme Corp. won the U.S. FDA approval for DELSTRIGO and PIFELTRO combination drugs. These will be used for the treatment of people suffering from human immunodeficiency virus (HIV)-1. Then, in 2018, Mylan Inc. launched Efavirenz tablets in the U.S. This product along with the combination of other antiretroviral agents for adults and pediatric patients boost the growth of the market. Though, many people suffering from this disease worldwide do not have access to timely treatment. It may hinder the market growth in the near future. Therefore, this factor boost the market growth.

Restraints/Challenges

• High Cost of Treatment

The growing cost of developing tests and devices can hamper the growth of the market. The huge cost associated with the testing of human immunodeficiency virus (HIV), the treatment processes which involves prolonged sessions, multiple drugs, which in turn hinders the growth of the market. This impedes the market growth.

• Lack of Awareness

Many people are unaware of their human immunodeficiency virus (HIV) infection status. For instance, as per the study conducted by BioMed Central LTD., it was found that among 467 participants suffering from human immunodeficiency virus (HIV), one-third of them were unaware of their infection status. The irregular availability of treatment of human immunodeficiency virus (HIV) and the increasing unawareness about the human immunodeficiency virus (HIV) infection is hindering the market growth.

This human immunodeficiency virus (HIV) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the human immunodeficiency virus (HIV) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Human Immunodeficiency Virus (HIV)Market

The COVID-19 pandemic has severely affected the import and export activities of healthcare products globally due to nationwide lockdowns. Moreover, the reduced number of new patient prescriptions in severely COVID-impacted areas has further decreased the demand for several antibiotic and antiretroviral human immunodeficiency virus (HIV) drugs. Thus, COVID-19 left a major impact on the human immunodeficiency virus (HIV) market.

Global Human Immunodeficiency Virus (HIV) Market Scope

The human immunodeficiency virus (HIV) market is segmented on the basis of diagnostics, drugs, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diagnostics

• Antigen/Antibody Test
• Antibody Test
• Nucleic Acid Tests (NATs)
• CD4T Cell Count
• Viral Load
• Drug Resistance
• Others

Drugs

• Protease inhibitors (PIs)
• Multi-class combination drugs
• Fusion inhibitors (FI)
• Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
• Others

Route of Administration

• Oral
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Human Immunodeficiency Virus Virus (HIV) Market Regional Analysis/Insights

The human immunodeficiency virus (HIV) market is analyzed and market size insights and trends are provided by diagnostics, drugs n, route of administration, end-users and distribution channel as referenced above.

The major countries covered in the human immunodeficiency virus (HIV) market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for human immunodeficiency virus (HIV) market throughout the forecasted period because of the growing healthcare and R&D expenditure, increasing patient awareness and major market players on novel technology or formulation of existing drugs. All these factors plays major role for the growth of human immunodeficiency virus (HIV) market.

Asia-Pacific dominates the market because of the high incidence cases of human immunodeficiency virus (HIV)-AIDS and number of generic drugs. Also, the expansion of the expenditure on the healthcare sector is further boosting the growth of the market. The increasing population in India and China would increase the demand for human immunodeficiency virus (HIV) drugs in the upcoming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data. 

Competitive Landscape and Global Human Immunodeficiency Virus (HIV) Market Share Analysis

The human immunodeficiency virus (HIV) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to human immunodeficiency virus (HIV) market.

Key players operating in the human immunodeficiency virus (HIV) market include:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Bristol-Myers Squibb Company (U.S.)
• AstraZeneca (U.K.)
• GSK plc (U.K.)
• Merck & Co., Inc. (U.S.)
• Novartis AG (Switzerland)
• Pfizer Inc. (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Mylan N.V. (U.S.)
• Sanofi (France)
• Bayer AG (Germany)
• ViiV Healthcare group of companies (U.K.)
• Genentech, Inc (U.S.)